• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    2seventy bio, Inc. - Common Stock (NQ: TSVT )

    4.950 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about 2seventy bio, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 Next >
    2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
    From 2seventy bio, Inc.
    Via Business Wire
    Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
    Novo Nordisk's Alhemo (concizumab) receives a positive opinion from the EMA's CHMP for hemophilia A or B with inhibitors. The once-daily subcutaneous treatment showed significant bleeding reduction in... 
    Via Benzinga
    TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
    2seventy bio halts enrollment in its KarMMa-9 trial for Abecma, saving $80 million and focusing on profitability by 2025. Despite the decision, the company expects strong growth following FDA approval... 
    Via Benzinga
    Exposures Product Safety
    2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
    From 2seventy bio
    Via Business Wire
    2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
    From 2seventy bio, Inc.
    Via Business Wire
    3 Hidden Stock Gems That Wall Street Is Overlooking
    If you play the long game and have a suitable risk tolerance, you can find overlooked stock gems like these three. 
    Via InvestorPlace
    Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
    2seventy Bio finalized an asset purchase agreement with Novo Nordisk involving the Hemophilia A program and in vivo gene editing technology. The 2seventy bio team will join Novo Nordisk, focusing on... 
    Via Benzinga
    2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Participate in Upcoming Investor Conferences
    From 2seventy bio, Inc.
    Via Business Wire
    TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
    TSVT stock results show that 2seventy bio met analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
    Via InvestorPlace
    2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
    From 2seventy bio, Inc.
    Via Business Wire
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
    Via Benzinga
    Exposures Product Safety
    FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
    FDA approves Bristol-Myers Squibb and 2seventy Bio Abecma (ide-cel) for relapsed or refractory multiple myeloma after ≥2 prior therapies. Extends progression-free survival by 13.3 months vs. standard... 
    Via Benzinga
    Exposures Product Safety
    U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
    From Bristol Myers Squibb
    Via Business Wire
    2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
    From 2seventy bio, Inc.
    Via Business Wire
    Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Shares of Science Applications International Corporation (NYSE: SAIC) fell sharply during Monday’s session after the company reported financial fourth-quarter EPS below estimates. 
    Via Benzinga
    FDA Adcomm Favors Expanded Use Of Johnson & Johnson, Bristol Myers' CAR-T Therapies For Type Of Blood Cancer
    FDA's adcomm recommends expanded use of Bristol Myers Squibb's Abecma for triple-class exposed relapsed or refractory multiple myeloma, based on Phase 3 study results. Positive vote for Johnson &... 
    Via Benzinga
    Exposures Product Safety
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Why Nuvei Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
    Shares of Nuvei Corp (NASDAQ: NVEI) rose sharply in today’s pre-market trading following a report indicating the company is in buyout talks with Advent International. Nuvei shares jumped 14.1% to... 
    Via Benzinga
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
    Pre-market stock movers are the perfect way to start the week as we dive into the biggest stories moving shares on Monday! 
    Via InvestorPlace
    FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
    From Bristol Myers Squibb
    Via Business Wire
    Why Cardlytics Shares Are Trading Higher By Around 37%; Here Are 20 Stocks Moving Premarket
    Shares of Cardlytics, Inc. (NASDAQ: CDLX) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter earnings. 
    Via Benzinga
    Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
    Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
    Via Benzinga
    < Previous 1 2 3 4 5 6 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.